The disclosure relates in part to the discovery that slow-flow vascular malformations (which can be venous and/or lymphatic) can be treated using direct intralesional delivery of an active drug, such as but not limited to a mTOR inhibitor, such as but not limited to temsirolimus, or a salt or solvate thereof.

The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrroll-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrroll-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

A method of increasing the solubility of a water-insoluble or slightly water-soluble hydrophobic organic compound in an aqueous solvent includes adding a saponin component selected from escin, glycyrrhizin, and Quillaya saponaria extract to the aqueous solvent in an amount sufficient to trigger the formation of micelles, wherein in a first step the hydrophobic organic compound is pre-dissolved in an organic solvent, and in a second step the organic solvent comprising the pre-dissolved compound is admixed to the aqueous solvent, whereby at least a part of the insoluble or slightly soluble hydrophobic organic compound gets solubilized and dissolved in the aqueous solvent, yielding an aqueous composition having an increased concentration of said organic compound dissolved therein. Also indicated are pharmaceutical or cosmetic compositions including a water-insoluble or slightly water-soluble organic compound dissolved in an aqueous solvent at substantially increased concentrations.

A method of increasing the solubility of a water-insoluble or slightly water-soluble hydrophobic organic compound in an aqueous solvent includes adding a saponin component selected from escin, glycyrrhizin, and Quillaya saponaria extract to the aqueous solvent in an amount sufficient to trigger the formation of micelles, wherein in a first step the hydrophobic organic compound is pre-dissolved in an organic solvent, and in a second step the organic solvent comprising the pre-dissolved compound is admixed to the aqueous solvent, whereby at least a part of the insoluble or slightly soluble hydrophobic organic compound gets solubilized and dissolved in the aqueous solvent, yielding an aqueous composition having an increased concentration of said organic compound dissolved therein. Also indicated are pharmaceutical or cosmetic compositions including a water-insoluble or slightly water-soluble organic compound dissolved in an aqueous solvent at substantially increased concentrations.

The present invention relates to a composition for enhancing a survival rate of stem cells, including an immunosuppressant, and to a use thereof. According to the present invention, a survival rate of stem cells can be remarkably enhanced using a composition including an immunosuppressant, and a therapeutic effect of stem cells can be improved on the basis of the enhancement. The composition can overcome an immune response caused by the administration of xenogeneic cells so as to accurately verify the stability and efficacy of cells, and thus will be able to be utilized as a mesenchymal stem cell therapeutic agent that maximizes a therapeutic effect of stem cells.

The present invention relates to a composition for enhancing a survival rate of stem cells, including an immunosuppressant, and to a use thereof. According to the present invention, a survival rate of stem cells can be remarkably enhanced using a composition including an immunosuppressant, and a therapeutic effect of stem cells can be improved on the basis of the enhancement. The composition can overcome an immune response caused by the administration of xenogeneic cells so as to accurately verify the stability and efficacy of cells, and thus will be able to be utilized as a mesenchymal stem cell therapeutic agent that maximizes a therapeutic effect of stem cells.

The present invention provides pharmaceutical compositions comprising solid nanoparticles, wherein the solid nanoparticles comprise i) an effective amount of a therapeutically active agent, wherein the therapeutically active agent is a substantially water insoluble prodrug; and ii) a biocompatible polymer.

The present invention provides pharmaceutical compositions comprising solid nanoparticles, wherein the solid nanoparticles comprise i) an effective amount of a therapeutically active agent, wherein the therapeutically active agent is a substantially water insoluble prodrug; and ii) a biocompatible polymer.

The present invention relates to anti-human OX40L antibodies, new medical uses and methods.